T

TG Therapeutics
D

TGTX

32.200
USD
1.29
(4.17%)
Market Closed
Volume
0
EPS
0
Div Yield
-
P/E
-321
Market Cap
5,012,423,755
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CRVS
    -0.08000
    (-1.57%)
    5.01000 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    J
    JNCE
    0.08500
    (5.31%)
    1.68000 USD
    K
    KPTI
    0.00170
    (0.26%)
    0.64430 USD
    M
    MYOV
    0
    (0%)
    0.000000 USD
    P
    PBYI
    -0.04000
    (-1.43%)
    2.75500 USD
    More
News

Title: TG Therapeutics

Sector: Healthcare
Industry: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.